Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial.

Cancer medicine·2026
Same author

Corrigendum to "Target attainment with continuously administered cefotaxime in critically ill patients - A retrospective cohort study". [Journal of Critical Care (2026) Start page (t.b.a.)-End page (t.b.a.)/155264].

Journal of critical care·2025
Same author

Target attainment with continuously administered cefotaxime in critically ill patients - a retrospective cohort study.

Journal of critical care·2025
Same author

Improving long-term storage of liquid-preserved bovine semen: Effect of extender, cooling protocol and holding temperature on sperm quality and fertility.

Theriogenology·2025
Same author

Open Spinal Dysraphism Without Hindbrain Herniation-Natural History and Postnatal Outcome.

Prenatal diagnosis·2025
Same author

Transport-related influences on the quality of liquid-preserved boar sperm: A review.

Animal reproduction science·2024

Related Experiment Video

Updated: Jul 13, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

[Modified platelet aggregation test in patients on ASA and/or clopidogrel].

C Eder1, U Funke, M Schulze

  • 1Klinikum Löbau-Zittau, Klinik für Innere Medizin, Görlitzer Str. 8, 02763 Zittau. innere.zi@kllz.de

Hamostaseologie
|August 19, 2007
PubMed
Summary

Many patients with arterial thrombosis experience inadequate platelet inhibition from antiplatelet drugs like aspirin (ASA) and clopidogrel. Aggregometry testing revealed significant failures in achieving desired platelet aggregation inhibition, highlighting a clinical challenge.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Related Experiment Videos

Last Updated: Jul 13, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Antiplatelet therapy with aspirin (ASA) and clopidogrel is crucial for preventing arterial thrombosis.
  • Monitoring the efficacy of these drugs in inhibiting platelet aggregation is essential for patient management.

Purpose of the Study:

  • To evaluate the effectiveness of aggregometry in assessing platelet inhibition by various doses of ASA and clopidogrel, alone or in combination.
  • To determine the failure rates of achieving adequate platelet inhibition in patients with arterial thrombosis.

Main Methods:

  • A modified platelet aggregation test was employed to measure maximum aggregation in response to ADP, collagen, adrenalin, and arachidonic acid.
  • Reference values were established from healthy individuals, and a scoring system was developed to detect inadequate platelet inhibition.
  • Patients received ASA (30-300 mg/d), clopidogrel (75 mg/d), or combination therapy (ASA 100 + clopidogrel 75 mg/d).

Main Results:

  • Significant delays in maximum platelet aggregation were observed in patients on ASA and combination therapy compared to controls.
  • Patients on clopidogrel alone showed prolonged aggregation when induced by ADP, collagen, and arachidonic acid.
  • Failure rates for adequate platelet inhibition were 27% for ASA 100 mg/d, 26% for clopidogrel 75 mg/d, and 7% for combination therapy.

Conclusions:

  • Platelet inhibition monitoring via aggregometry is vital as many patients with arterial thrombosis do not achieve adequate inhibition with standard antiplatelet therapies.
  • The study highlights potential limitations in achieving consistent therapeutic effects with individual antiplatelet agents, underscoring the need for personalized monitoring.